Phathom Pharmaceuticals, Inc. (PHAT) Stock
PHAT has an Alpha Score of 12 out of 100 (poor), computed on Nov 10, 2026 from 2 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported PHAT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $36.63M.
What is PHAT's Alpha Score?
How it works →Alpha Score of 12 reflects poor overall profile with poor momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 10, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own PHAT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.38M | $36.63M | -16% |
| Point72 Steve Cohen | 1.02M | $11.09M | NEW |
| Marshall Wace | 666K | $7.23M | -23% |
| Renaissance Technologies Jim Simons (founder) | 226K | $2.46M | -26% |
| Citadel Ken Griffin | 185K | $2.01M | -52% |
| D.E. Shaw David Shaw | 96K | $1.04M | -28% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Phathom Pharmaceuticals, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Jan 24, 24 | Takeda Pharmaceutical Co Ltd | 10%+ Owner | SELL | 3.70M | $30.0M |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are PHAT's key statistics?
Key statistics as of Nov 2, 2026
How does PHAT's valuation compare with the Healthcare sector?
| Metric | PHAT | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -41.34% | 3.60% | 175 |
| Return on equity | -232.78% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
PHAT price chart
Powered by TradingViewWhat does Phathom Pharmaceuticals, Inc. do?
Phathom Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases related to acid. Its flagship product, VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, is approved for adults with erosive gastroesophageal reflux disease (GERD) and heartburn, as well as non-erosive GERD. The company also offers VOQUEZNA Triple Pak and VOQUEZNA Dual Pak combination therapies for treating Helicobacter pylori infections. These products address key unmet needs in the GI sector by providing superior acid suppression compared to traditional proton pump inhibitors. Phathom Pharmaceuticals Inc. emphasizes commercializing these therapies in the United States, supported by ongoing clinical data presentations at medical conferences and prescription growth tracking. Founded in 2018 and headquartered in Florham Park, New Jersey, the company plays a significant role in advancing innovative GI treatments within the biopharmaceutical market.